Cell Therapeutics

Cell Therapeutics has obtained conditional approval in Europe for their lymphoma drug, Pixuvri. The European Commission has given the okay for Pixuvri (pixantrone) as monotherapy for the treatment of adults with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL), making it the first authorised treatment in this patient setting in the continent. The decision